OTHER NEUROSCIENCE — Sales to customers (Note 9)
Johnson & Johnson OTHER NEUROSCIENCE — Sales to customers (Note 9) increased by 6.9% to $262.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 5.4%, from $277.00M to $262.00M. Over 4 years (FY 2021 to FY 2025), OTHER NEUROSCIENCE — Sales to customers (Note 9) shows a downward trend with a -15.7% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.
Analysis
How to read this metric
An increase indicates successful market penetration or expanded adoption of secondary neurological therapies, while a decrease may suggest competitive pressure or product lifecycle maturity.
Detailed definition
This metric represents the total net revenue generated from the sale of products within the company's secondary neurosci...
Peer comparison
Comparable to secondary therapeutic segment revenues reported by other large-cap pharmaceutical companies, often categorized under specialized or niche therapeutic areas.
jnj_segment_other_neuroscience_sales_to_customers_note_9Historical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $464.00M | $379.00M | $809.00M | $467.00M | $433.00M | $393.00M | $441.00M | $423.00M | $386.00M | $340.00M | $404.00M | $345.00M | $294.00M | $281.00M | $255.00M | $277.00M | $270.00M | $256.00M | $245.00M | $262.00M |
| QoQ Change | — | -18.3% | +113.5% | -42.3% | -7.3% | -9.2% | +12.2% | -4.1% | -8.7% | -11.9% | +18.8% | -14.6% | -14.8% | -4.4% | -9.3% | +8.6% | -2.5% | -5.2% | -4.3% | +6.9% |
| YoY Change | — | — | — | — | -6.7% | +3.7% | -45.5% | -9.4% | -10.9% | -13.5% | -8.4% | -18.4% | -23.8% | -17.4% | -36.9% | -19.7% | -8.2% | -8.9% | -3.9% | -5.4% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Johnson & Johnson's other neuroscience — sales to customers (note 9)?
- Johnson & Johnson (JNJ) reported other neuroscience — sales to customers (note 9) of $262.00M in Q1 2026.
- How has Johnson & Johnson's other neuroscience — sales to customers (note 9) changed year-over-year?
- Johnson & Johnson's other neuroscience — sales to customers (note 9) decreased by 5.4% year-over-year, from $277.00M to $262.00M.
- What is the long-term trend for Johnson & Johnson's other neuroscience — sales to customers (note 9)?
- Over 4 years (2021 to 2025), Johnson & Johnson's other neuroscience — sales to customers (note 9) has grown at a -15.7% compound annual growth rate (CAGR), from $2.07B to $1.05B.
- What does other neuroscience — sales to customers (note 9) mean?
- The total revenue generated from the company's secondary line of neuroscience products.